Compare Citius Pharmaceuticals Inc (CTXR) vs Honeywell International Inc (HON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Honeywell International Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.79M), while Honeywell International Inc trades at $207 (market cap $65.96B). The key difference: Honeywell International Inc is far larger — about 4783.2× Citius Pharmaceuticals Inc's market cap, and Honeywell International Inc pays a 1.35% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Honeywell International Inc for 90 Days on average.
| CTXR | HON | |
|---|---|---|
Market Cap | $13.79M | $65.96B |
Volume | 156,684 | 2,009,898 |
Sector | Health | Industrials |
52-Week High | $1.82 | $248.79 |
52-Week Low | $0.48 | $188.14 |
Typical Hold Time | 16 Days | 90 Days |
Enterprise Value | $3.96M | $90.75B |
Dividend Yield | — | 1.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, but remains in a bearish technical trend with negative profitability metrics. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR sales, though net income margin remains deeply negative at -651.27%. Analyst consensus is strongly bullish with 5 buy ratings and a $5.00 price target, representing significant upside potential from current levels.
While CTXR shows promising commercial progress with its oncology drug launch, the stock faces substantial execution risks due to persistent losses and cash burn. The bullish analyst sentiment contrasts with weak fundamentals, creating a high-risk, high-reward scenario for investors betting on successful commercialization of LYMPHIR in the $400M+ CTCL market.
Honeywell International (HON) trades at $206.6, down 2.95% on the day, with a bearish technical signal despite strong fundamentals including a low P/E of 8 and robust profitability margins. Recent quarterly earnings have consistently beaten expectations, and the company secured a significant $300 million refinery project with Dangote. Analyst consensus remains strongly bullish with a $259.25 price target, representing 25% upside potential from current levels.
The stock presents a compelling value opportunity given its discounted valuation metrics and consistent earnings outperformance, though investors face near-term technical headwinds and execution risks from the company's recent strategic transformation into a pure-play automation business following the spin-off of its aerospace and advanced materials divisions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →
